CDiddy, I did not read the emerging growth piec
Post# of 148179
I did not read the emerging growth piece as closely as I should have. While the discussion is a rehash of the detailed analysis by incredibly knowledgeable posters here (Many, many thanks!),
The 64% reduction in SAEs versus placebo can only rationally indicate the efficacy of leronlimab.
The line that stuck out and I believe to be true is:
“ Investors need to wake up and realize that CYDY won the game but we just don’t know what the final score was. ”
To borrow again from others here,
BOOM